The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825.
Jeffrey Scott Wefel
Consultant or Advisory Role - Genentech/Roche
Research Funding - Genentech/Roche
Stephanie L. Pugh
No relevant relationships to disclose
Terri S. Armstrong
Research Funding - Genentech/Roche
Mark R. Gilbert
Consultant or Advisory Role - EMD Serono; Genentech; Merck; Novartis
Honoraria - EMD Serono; Genentech; Merck; Novartis
Research Funding - Genentech; GlaxoSmithKline; Merck
Minhee Won
No relevant relationships to disclose
Merideth M Wendland
No relevant relationships to disclose
David Brachman
No relevant relationships to disclose
Ritsuko Komaki
No relevant relationships to disclose
Ian R. Crocker
No relevant relationships to disclose
H. Ian Robins
Consultant or Advisory Role - Genentech
Research Funding - Genentech
R. Jeffrey Lee
No relevant relationships to disclose
Minesh P. Mehta
Consultant or Advisory Role - Genentech; Merck
Stock Ownership - Accuray
Honoraria - Merck